
Myomo (MYO) Stock Forecast & Price Target
Myomo (MYO) Analyst Ratings
Bulls say
Myomo Inc. has demonstrated a significant increase in its reimbursement pipeline, growing from 1,389 units in Q4 to 1,669 in the most recent quarter, indicating strong demand for its myoelectric orthosis products. The company is poised for enhanced revenue growth, as approximately 22% of its projected revenue in 2024 is anticipated to come from orthotics and prosthetics providers, while also redirecting its focus towards the extensive Medicare market. Additionally, the favorable ruling from the Centers for Medicare & Medicaid Services (CMS) in March 2024, which includes MyoPro in Medicare Part B benefits, substantially expands the accessible market and strengthens Myomo's competitive positioning.
Bears say
Myomo Inc. has recently lowered its guidance for 2025 revenue expectations to a range of $40 – 42 million, down from a prior estimate of $50 – 53 million, indicating potential financial difficulties ahead. The company is also experiencing challenges with its marketing efforts, resulting in poorer lead quality and pipeline conversions, which are essential for sustaining revenue growth. Additionally, the decrease in the backlog of authorized insurance claims, from 272 in Q4 to 208, underscores a declining demand for its products that could further exacerbate the company's financial outlook.
This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.
Myomo (MYO) Analyst Forecast & Price Prediction
Start investing in Myomo (MYO)
Order type
Buy in
Order amount
Est. shares
0 shares